As the debate over drug pricing persists on Capitol Hill, The Pew Charitable Trusts’ drug safety project is working to educate members of Congress about the dangers of allowing compounded drugs—drugs made by pharmacists—to serve as a low-cost alternative to FDA-approved medications. In advance of the U.S. House of Representatives’ Feb. 4 Oversight and Government Reform Committee hearing “Developments in the Prescription Drug Market: Oversight,” Pew sent a letter to committee members, urging them to protect patients by preserving the drug approvals process.